SCHEMBL17933751

SCHEMBL17933751

CCCCNc1nc2ccccc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.64
RAB9A P51151 11/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
RIPK1 Q13546 2/20 0.58
QPCT Q16769 1/20 0.58
ALDH1A1 P00352 3/20 0.57
MAPT P10636 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
LMNA P02545 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
NFKB1 P19838 1/20 0.56
STAT1 P42224 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
GAA P10253 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
IDO1 P14902 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4528378 0.95 NPC1 (0.61) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL22039979 0.94 NPC1 (0.60) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL22040024 0.94 NPC1 (0.60) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL17570161 0.94 NPC1 (0.60) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL19497780 0.94 NPC1 (0.60) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL1664350 0.90 NPC1 (0.67) NPC1RAB9ASMN1; SMN2QPCTALDH1A1
Hydrochloric Acid SCHEMBL2124383 0.89 NPC1 (0.65) NPC1RAB9ASMN1; SMN2QPCTALDH1A1
Hydrochloric Acid SCHEMBL7109842 0.87 NPC1 (0.63) NPC1RAB9ASMN1; SMN2QPCTALDH1A1
SCHEMBL22040020 0.86 NPC1 (0.58) NPC1RAB9ASMN1; SMN2RIPK1QPCT
SCHEMBL11074021 0.84 NPC1 (0.63) NPC1RAB9ASMN1; SMN2QPCTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2022-06-30 US disclosed
US-20210228550-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2021-07-29 US disclosed
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2021-03-16 US disclosed
WO-2020150473-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 WO disclosed
US-20200165215-A1 METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE DIC CORPORATION (JP) 2020-05-28 US disclosed
US-20190209531-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2019-07-11 US disclosed
WO-2019102922-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER OF SAME, OPTICALLY ANISOTROPIC BODY, AND DISPLAY ELEMENT DIC株式会社 2019-05-31 WO disclosed
WO-2018101122-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY IN WHICH SAME IS USED DIC株式会社 2018-06-07 WO disclosed
US-20180031738-A1 RETARDATION PLATE AND CIRCULARLY POLARIZING PLATE DIC CORPORATION (JP) 2018-02-01 US disclosed
WO-2018016567-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY USING SAME DIC株式会社 2018-01-25 WO disclosed
US-20180000793-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis ABEL-SANTOS ERNESTO (US) 2018-01-04 US disclosed
US-20170306233-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY DIC CORPORATION (JP) 2017-10-26 US disclosed
US-20170306233-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY DIC CORPORATION (JP) 2017-10-26 US disclosed
WO-2017090418-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY USING SAME DIC株式会社 2017-06-01 WO disclosed
WO-2016127102-A2 INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS ABEL-SANTOS ERNESTO (US) 2016-08-11 WO disclosed
WO-2016114254-A1 RETARDATION PLATE AND CIRCULARLY POLARIZING PLATE DIC株式会社 2016-07-21 WO disclosed
WO-2016114346-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY USING SAME DIC株式会社 2016-07-21 WO disclosed
WO-2016114253-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY USING SAME DIC株式会社 2016-07-21 WO disclosed
CN-102321046-B Method for preparing 2-(N-alkyl)aminothiazole and 2-(N-alkyl) aminooxazole derivative by N-alkylation reaction UNIV NANJING SCIENCE & TECH 2014-03-26 CN disclosed
CN-102321046-A Method for preparing 2-(N-alkyl)aminothiazole and 2-(N-alkyl) aminooxazole derivative by N-alkylation reaction UNIV NANJING SCIENCE & TECH 2012-01-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis CASP3, SI, PYCARD NPC1 1750/4885RAB9A 4497/4885SMN1; SMN2 4241/4885
US-20200165215-A1 METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE HAO2, IDH2, HACL2 NPC1 2261/4885RAB9A 3845/4885SMN1; SMN2 4509/4885
US-20170306233-A1 POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY SMC4, PHOSPHO1, SMCHD1 NPC1 2476/4885RAB9A 4246/4885SMN1; SMN2 1598/4885
US-20190209531-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD NPC1 1750/4885RAB9A 4497/4885SMN1; SMN2 4241/4885
US-20220204497-A1 NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME TPX2, AIMP2, CDYL2 NPC1 1722/4885RAB9A 2686/4885SMN1; SMN2 1981/4885
US-20210228550-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD NPC1 1750/4885RAB9A 4497/4885SMN1; SMN2 4241/4885
US-20180000793-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD NPC1 1750/4885RAB9A 4497/4885SMN1; SMN2 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.